** Shares of medtech firm Neuronetics STIM.O down 18.8% at $2.89 post-market as co seeks equity raise
** Malvern, Pennsylvania-based co, which offers its NeuroStar Therapy to treat major depressive disorder, launches stock offering
** Targeted deal size not disclosed
** Co has ~55.65 mln shares outstanding for roughly $200 mln market value and ~27 mln shares of public float, according to LSEG data
** Canaccord Genuity is sole bookrunner for offering
** STIM shares on Thurs rose 8.9% to close at $3.56. YTD, stock up 121%
** Avg rating among 4 analysts is "buy" with $3 median PT - LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。